Disclaimer
Access to the information and documents on this part of the website is restricted for regulatory reasons. You are requested to review the following information and make the following confirmation each time you seek to access this restricted information. Your confirmation must be true and accurate.
DISCLAIMER – IMPORTANT
Due to applicable legal restrictions, the information contained in this section of the website is restricted and is not for release, publication or distribution, directly or indirectly, in whole or in part, in or into the United States of America (including its territories and possessions, any state of the United States and the District of Columbia), the United Kingdom, Australia, Canada, Hong Kong, Israel, Japan, New Zealand, Singapore, South Africa or Switzerland, or any other jurisdiction in which such release, publication or distribution might constitute a violation of the local securities laws or regulations of such jurisdiction. We apologise for any inconvenience this may cause. Click here to return to the homepage.
Important information
Access to the information and documents on this portion of the website is restricted for regulatory reasons. You are requested to review the following information and make the following confirmation each time you seek to access this restricted information. Your confirmation must be true and accurate.
The information contained in this section of the website of Oncopeptides AB (publ) (the “Company”) (a) is only intended for, and may only be accessed by, or distributed or disseminated, directly or indirectly, in whole or in part, to (i) persons resident and physically present outside the United States of America (including its territories and possessions, any state of the United States and the District of Columbia, the “United States”), Australia, Canada, Hong Kong, Israel, Japan, New Zealand, Singapore, South Africa or Switzerland and resident and physically present in a jurisdiction where to do so will not constitute a violation of the local securities laws or regulations of such jurisdiction, and (b) does not constitute an offer to sell or the solicitation of an offer to buy or acquire, any securities of the Company in the United States, Australia, Canada, Hong Kong, Israel, Japan, New Zealand, Singapore, South Africa, Switzerland or any other jurisdiction where to do so might constitute a violation of the local securities laws or regulations of such jurisdiction.
The securities of the Company referred to in this section of the Company’s website (the “Securities”) have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) or with any securities regulatory authority of any state of the United States and may not be offered or sold within the United States unless the Securities are registered under the Securities Act or pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. In the United States, the Securities will be sold only to “qualified institutional buyers” (as defined in Rule 144A in the Securities Act) (“QIBs”), pursuant to an exemption from registration under the Securities Act. All offers and sales of the Securities outside the United States will be made in compliance with Regulation S under the Securities Act and in accordance with applicable law.
The Securities have not been and will not be registered under the applicable securities laws of Australia, Canada, Hong Kong, Israel, Japan, New Zealand, Singapore, South Africa, Switzerland or any other jurisdiction in which it would be unlawful or would require registration or other measures, and therefore may not be offered or sold or for the account or benefit of any person having a registered address in, or located or resident in, Australia, Canada, Hong Kong, Israel, Japan, New Zealand, Singapore, South Africa, Switzerland or any other jurisdiction in which it would be unlawful or would require registration or other measures.
In the United Kingdom, the information contained in this section of the Company’s website is only being distributed to and is only directed at “Qualified Investors” within the meaning of Article 2(e) of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 as it forms part of domestic law in the United Kingdom by virtue of the European Union (Withdrawal) Act 2018 (the “EUWA”) (the “UK Prospectus Regulation”), who are (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or (ii) high net worth companies, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons above together being referred to as “relevant persons”). The Securities are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on the information contained in this section of the Company’s website.
This information and offering are only addressed to and directed at persons in member states of the European Economic Area (the “EEA”), who are “Qualified Investors” within the meaning of Article 2 (e) of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 (the “Prospectus Regulation”). The securities are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with Qualified Investors. This information should not be acted upon or relied upon in any member state of the EEA by persons who are not Qualified Investors.
Access to the information contained in this section of the Company’s website may be illegal in certain jurisdictions, and only certain categories of persons may be authorised to access such information. All persons residing outside of Sweden who wish to have access to the information contained in this section of the Company’s website should first ensure that they are not subject to local laws or regulations that prohibit or restrict their right to access this section of the Company’s website, or require registration or approval for any acquisition of Securities by them. No such registration or approval has been or will be obtained outside of Sweden.
The Company assumes no responsibility if there is a violation of applicable law and regulations by any person.
If you are not permitted to view materials on this webpage or are in any doubt as to whether you are permitted to view these materials, please exit this webpage.
I therefore certify that:
- 1. I am (i) resident and physically present in a country outside the United Kingdom, the United States, Australia, Canada, Hong Kong, Israel, Japan, New Zealand, Singapore, South Africa and Switzerland or any other jurisdiction in which the release, distribution or publication would be unlawful or require registration or any other measure in accordance with applicable law or (ii) a Qualified Investor within the EEA, a relevant person in the United Kingdom;
- 2. I am authorised to access the information contained in this section of the Company’s website without being subject to any legal restriction and without any further action required by the Company; and
- I have read, understand and agree to comply with all of the restrictions set forth above.
Press release
Oncopeptides carries out rights issue of approximately SEK 150 million and provides update regarding the potential partnership in Japan
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, ISRAEL, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO BUY SECURITIES IN ONCOPEPTIDES AB (PUBL). SEE ALSO THE SECTION “IMPORTANT INFORMATION” BELOW IN THIS DOCUMENT.
Oncopeptides AB (publ) (“Oncopeptides” or the “Company”) (Nasdaq Stockholm: ONCO) hereby announces that the Board of Directors has resolved to carry out a partially guaranteed new share issue of approximately SEK 150 million with preferential rights for the Company’s existing shareholders (the “Rights Issue”) based on the authorization granted by the Annual General Meeting on 22 May 2025. The purpose of the Rights Issue is to finance the ongoing commercialization of Pepaxti® in Europe until the Company expects to become cash flow positive by the end of 2026, and also to secure early progression of the Company’s portfolio of pre-clinical assets.
HealthCap VIII LP has committed to subscribe for SEK 15.5 million and certain members of the Board of Directors of the Company and senior executives intend to enter into binding subscription undertakings after the publication of the Company’s interim report for the second quarter of 2025. In addition, several guarantors have provided guarantee commitments which, in total, amount to SEK 113.8 million. Under the guarantee commitments, the guarantors shall subscribe for any shares not otherwise subscribed for up to SEK 130 million (the “Committed Amount”). In total, the Company has received a subscription undertaking, subscription intentions and guarantee commitments covering approximately 87 percent of the Rights Issue, corresponding to approximately SEK 130 million.
As first communicated during the first quarter 2025, the Company is making progress in its partnership negotiations for Japan. The Company continues its negotiations with well-established sizeable Japanese pharma companies for the licensing of Pepaxti for the Japanese market and are in advanced discussions with, and have received a non-binding offer from, one highly reputable partner and has in addition thereto also received a non-binding offer from another potential partner which the Company is considering in parallel.
“This far in 2025, Oncopeptides has taken substantial steps on its journey to cash flow positive by the end of 2026. With our earlier than expected entry into the Italian market and even higher-than-expected second quarter sales growth, we see a good momentum for our European commercialization,” says Sofia Heigis, CEO of Oncopeptides. “As we continue our discussions to access the Japanese market for Pepaxti with what would be a landmark deal for Oncopeptides, this cash infusion ensures our ability to remain fully dedicated to our commercialization efforts and sales growth. It also enables us to secure progress with our pipeline assets, in which we see major global opportunities in multiple indications with high unmet medical needs.”
Summary of the Rights Issue
- The Rights Issue is carried out to provide additional runway for the ongoing commercialization of Pepaxti in Europe and secure early progression of the Company’s portfolio of pre-clinical assets.
- The proceeds from the Rights Issue are deemed by the Board of Directors to be sufficient to reach profitability and cash flow positivity, regardless of if the Company only receives the Committed Amount and regardless of if the Company is successful in the negotiations regarding partnerships in Japan.
- The Rights Issue is covered to approximately 87 percent by a subscription undertaking, subscription intentions and guarantee commitments.
- The record date for the Rights Issue is 28 August 2025 and the subscription period will run from 1 September 2025 until 15 September 2025.
- The subscription price of SEK 3.20 per share corresponds to a discount of approximately 32 percent compared to the theoretical price (so called TERP – theoretical ex-rights price) based on the closing price of Oncopeptides’ share on Nasdaq Stockholm on 20 August 2025.
Update on partnership negotiations in Japan
As first communicated during the first quarter 2025, the Company is involved in partnership negotiations in Japan, have made further progress over the last months and is continuing its negotiations with well-established and sizeable Japanese pharma companies for the licensing of Pepaxti for the Japanese market. The Company is currently in advanced discussions with one highly reputable partner, with the due diligence process at a late stage, based on a non-binding offer which is in line with market practice and which includes several significant upfront and milestone payments and a double-digit royalty, with the partner assuming all costs related to regulatory activities and commercialization in Japan. The Company has in addition thereto also received a non-binding offer from another potential partner which the Company is considering in parallel. The partnership negotiations are non-binding at this time and there are no assurances that a binding agreement will be entered into or the timing thereof.
Background and reasons
Oncopeptides is a Swedish biotech company focused on the research, development and commercialization of targeted therapies for difficult-to-treat cancers. The company was founded 25 years ago and is today active in several important European markets, including Germany, Austria, Spain and Italy.
Assuming that the Rights Issue is fully subscribed, the Company will receive approximately SEK 150 million before deduction of transactions costs. The Company intends to use the net proceeds to provide additional runway for the ongoing commercialization of Pepaxti in Europe and to secure early progression of the Company’s portfolio of preclinical projects. The proceeds from the Rights Issue will strengthen the Company’s financial position and are expected to be sufficient to finance the Company until it becomes cash flow positive which is expected to occur in the fourth quarter of 2026, regardless of if the Company only receives the Committed Amount and regardless of if the Company is successful in the negotiations regarding partnerships in Japan.
Oncopeptides has recently reported on several important events regarding Pepaxti’s European commercialization and position in the market. The Rights Issue will provide the opportunity to boost the activities in Europe in order to fully exploit the positive news momentum.
The Company assesses that receiving an upfront Japan license payment is likely but not certain until a deal has been finalized, as with all partnership negotiations. If the Company receives such Japan license payment, the Company will direct the additional funding to advance the Company’s pipeline and more specifically OPD5 to become at least IND ready as the asset has the potential for multiple indications with high unmet needs including glioblastoma and multiple myeloma. For multiple myeloma, the development path to a global market as a second-generation Peptide Drug Conjugate (PDC) is, relative to other projects, de-risked based on the learnings from melflufen.
Terms of the Rights Issue
Those who are registered as shareholders of ordinary shares in Oncopeptides on the record date 28 August 2025, will receive one (1) subscription right for each existing ordinary share. The subscription right provides the holder with the preferential right to subscribe for new ordinary shares, where nine (9) subscription rights entitle the holder to subscribe for two (2) new ordinary shares. In addition, it will be possible for investors to apply for subscription of shares without subscription rights.
Should all shares not be subscribed for by virtue of subscription rights, the Board of Directors shall, within the framework of the maximum amount of the Rights Issue, decide on the allocation of ordinary shares which have not been subscribed for by virtue of subscription rights. In such case, ordinary shares shall:
- firstly, be allocated to those who have expressed an interest in subscribing and have subscribed for new ordinary shares by virtue of subscription rights, regardless if the subscriber were a shareholder on the record date or not, and in the event of oversubscription, in relation to the number of subscription rights each have exercised for subscription of new ordinary shares,
- secondly, be allocated to others whom have declared interest in subscribing for ordinary shares without exercising subscription rights, and in the event of oversubscription, in relation to the number of new ordinary shares specified in the respective subscription registration, and, to the extent that this is not possible, by lottery,
- thirdly and lastly, be allocated, up to the Committed Amount, to the investors who provided guarantees and in accordance with the conditions of their respective guarantee and, to the extent this cannot be done, by lottery.
The subscription price is SEK 3.20 per new ordinary share. Assuming that the Rights Issue is fully subscribed, the share capital will be increased by approximately SEK 5,216,392.88, from approximately SEK 25,084,314.69 to approximately SEK 30,300,707.56, by new issue of 46,947,534 new ordinary shares, resulting in the total number of shares increasing from 225,758,823 shares to 272,706,357 shares.
Shareholders who choose not to participate in the Rights Issue will, assuming that the Rights Issue is fully subscribed, have their shareholdings diluted by approximately 18.2 percent (based on the number of ordinary shares after completion of the Rights Issue). However, such shareholders have the opportunity to partially financially compensate for this dilution by selling their subscription rights.
The subscription period is expected to run from and including 1 September 2025 until and including 15 September 2025 and trading in subscription rights is expected to run from and including 1 September 2025 and until and including 10 September 2025. Furthermore, trading in paid subscribed shares (BTA) is expected to run from and including 1 September 2025 until and including 22 September 2025.
Subscription undertaking, subscription intentions and guarantee commitments
HealthCap VIII LP has committed to subscribe for SEK 15.5 million. Certain members of the Board of Directors of the Company and senior executives also intend to enter into binding subscription undertakings after the publication of the Company’s interim report for the second quarter of 2025 up to their respective pro-rata amounts and this commitment and these intentions correspond to approximately 11 percent of the Rights Issue. Several guarantors have agreed to guarantee approximately 76 percent of the Rights Issue, corresponding to approximately SEK 113.8 million, at a guarantee compensation of 8 percent of the guaranteed amount in cash. Under the guarantee commitments, the guarantors shall subscribe for any shares not otherwise subscribed for up to the Committed Amount. The Rights Issue is thus approximately 87 percent covered through the subscription undertaking and intentions, and guarantee commitments.
None of the above mentioned commitments are secured by bank guarantee, blocked funds, pledges or similar arrangements.
Lock-up undertakings
In connection with the Rights Issue, the Company has agreed to a lock-up undertaking, subject to customary exceptions, whereby the Company’s Board of Directors may not propose or resolve on any new share issuances for a period of 180 calendar days after the announcement of the outcome of the Rights Issue, provided, however, that the Company shall have the right to issue and transfer warrants to the European Investment Bank – EIB (in accordance with the agreement prior entered into between the Company and EIB). In addition, the members of the Board of Directors and senior management of Oncopeptides have agreed not to sell any shares in Oncopeptides for a period of 180 calendar days after the announcement of the outcome of the Rights Issue, subject to customary exceptions.
Disclosure document
Full terms of the Rights Issue and certain information about the Company will be presented in a disclosure document in accordance with Article 1.4 db of the Regulation (EU) 2017/1129 of the European Parliament and of the Council (the “Prospectus Regulation”). The disclosure document, prepared in accordance with Annex IX to the Prospectus Regulation, is expected to be published on or around 28 August 2025.
Preliminary timetable for the Rights Issue
| Last day of trading in shares including right to receive subscription rights | 26 August 2025 |
| First day of trading in shares excluding right to receive subscription rights | 27 August 2025 |
| Record date for right to receive subscription rights | 28 August 2025 |
| Publication of the disclosure document | 28 August 2025 |
| Trading in subscription rights | 1 – 10 September 2025 |
| Subscription period | 1 – 15 September 2025 |
| Trading in paid subscribed shares (BTA) | 1 – 22 September 2025 |
| Announcement of the outcome of the Rights Issue | Around 17 September 2025 |
Advisors
DNB Carnegie Investment Bank AB (publ) acts as Sole Global Coordinator and Joint Bookrunner in connection with the Rights Issue. Zonda Partners acts as Joint Bookrunner. Advokatfirman Vinge KB is legal adviser to the Company.